Nureca Limited has informed the exchange regarding Record date for Annual General Meeting.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Limited held its Board meeting on May 29, 2026, approving multiple items. The company reported audited standalone revenue of ₹1,472.10 million for FY26, up 28.4% from ₹1,146.40 million in FY25. PAT turned positive at ₹2.97 million versus a loss of ₹6.68 million in FY25, though Q4 saw a significant loss of ₹66.25 million. Operating cash flow improved dramatically from negative ₹188.18 million to positive ₹3.19 million. Key management changes include CFO Mr. Naresh Gupta's resignation (effective June 26, 2026) replaced by Mr. Chander Kant (effective June 27, 2026), and appointments of Ms. Smita Goyal as Additional Director (Whole Time Director). The board approved ₹100 crore incremental capex for manufacturing medical devices and healthcare products, plus additional land purchase for expansion. The 10th AGM is scheduled for July 28, 2026, with book closure from July 22-28, 2026. Statutory auditors issued an unmodified opinion on the financial results.
The company showed strong revenue growth of 28.4% and returned to profitability with an unmodified audit opinion, which is positive. However, the Q4 loss of ₹66.25 million and thin annual PAT of ₹2.97 million indicate operational challenges despite top-line growth. The CFO transition and capex plans suggest management focus on expansion, but shareholders should monitor Q4 performance trends.